CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-26 | Wang Xiaodong Director | Option exercise · Share Option (Right to Buy) 10b5-1 | −499,993 | 7 | ||
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −1,565 | $229.25 | $359K | 4,610 |
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −1,747 | $230.05 | $402K | 2,863 |
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −229 | $231.05 | $53K | 2,634 |
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −38 | $233.00 | $9K | 2,596 |
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −428 | $234.27 | $100K | 2,168 |
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −1,272 | $235.41 | $299K | 896 |
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −896 | $236.37 | $212K | 0 |
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −2,535 | $229.25 | $581K | 7,465 |
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −2,827 | $230.05 | $650K | 4,638 |
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −371 | $231.04 | $86K | 4,267 |
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −62 | $233.00 | $14K | 4,205 |
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −694 | $234.27 | $163K | 3,511 |
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −2,059 | $235.41 | $485K | 1,452 |
| 2024-10-08 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −1,452 | $236.37 | $343K | 0 |
| 2024-09-30 | Sharp Shalini Director | Grant or award | +8,151 | 8,151 | ||
| 2024-09-30 | Sharp Shalini Director | Grant or award · Share Option (Right to Buy) | +17,238 | 17,238 | ||
| 2024-09-30 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −1,202 | $237.10 | $285K | 0 |
| 2024-09-27 | Wang Lai Global Head of R&D | Sale 10b5-1 | −5,000 | $220.35 | $1.1M | 0 |
| 2024-09-19 | Wu Xiaobin President, COO & GM China | Sale 10b5-1 | −4,500 | $200.14 | $901K | 0 |
Page 36 of 71 · 1,406 trades